Inovio Pharmaceuticals (INO) Interest Coverage Ratio (2019 - 2024)
Inovio Pharmaceuticals' (INO) quarterly Interest Coverage Ratio came in at 163757.36 in Q3 2024, down 144067.96% year-over-year from N/an in Q4 2023, and down 92480.08% quarter-over-quarter from 176.88 in Q1 2024.
Powered by 
Analysis
Inovio Pharmaceuticals (INO) Interest Coverage Ratio (2019 - 2024) Analysis & Trends
Inovio Pharmaceuticals has disclosed Interest Coverage Ratio across 6 years of filings, most recently posting 163757.36 for Q3 2024.
- In Q3 2024, Interest Coverage Ratio fell 144067.96% year-over-year to 163757.36; the TTM figure through Jun 2025 stood at 573964.6 (down 347675.54% YoY), while the FY2024 annual figure was 632.05, down 436.93% from the prior year.
- Interest Coverage Ratio came in at 163757.36 for Q3 2024 at Inovio Pharmaceuticals, down from 176.88 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 9.0 in Q1 2020 to a low of 163757.36 in Q3 2024.
- Average Interest Coverage Ratio over 5 years is 9219.41, with a median of 122.01 recorded in 2021.
- Year-over-year, Interest Coverage Ratio jumped 79.3% in 2020 and sank 144067.96% in 2024.
- Over 5 years, Interest Coverage Ratio stood at 27.47 in 2020, then slumped by 699.62% to 219.67 in 2021, then increased by 18.76% to 178.46 in 2022, then jumped by 45.63% to 97.03 in 2023, then sank by 168671.39% to 163757.36 in 2024.
- Per Business Quant data, the three most recent Interest Coverage Ratio figures were 163757.36 in Q3 2024, 176.88 in Q1 2024, and 97.03 in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 5.22 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -42.08 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 117.59 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 493.00 |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 2.82 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Inovio Pharmaceuticals | 104.88 Mn | 104.88 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2024 | -163,757.36 |
| Mar 31, 2024 | -176.88 |
| Dec 31, 2023 | -97.03 |
| Sep 30, 2023 | -113.59 |
| Jun 30, 2023 | -118.16 |
| Mar 31, 2023 | -140.20 |
| Dec 31, 2022 | -178.46 |
| Sep 30, 2022 | -114.06 |
| Jun 30, 2022 | -332.19 |
| Mar 31, 2022 | -228.82 |
| Dec 31, 2021 | -219.67 |
| Sep 30, 2021 | -125.85 |
| Jun 30, 2021 | -178.27 |
| Mar 31, 2021 | -102.44 |
| Dec 31, 2020 | -27.47 |
| Sep 30, 2020 | -18.31 |
| Jun 30, 2020 | -11.66 |
| Mar 31, 2020 | -9.00 |
| Dec 31, 2019 | -11.40 |
| Sep 30, 2019 | -9.86 |